Literature DB >> 35816267

IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.

Yoko Fujita1, Luis Nunez-Rubiano2, Antonio Dono1, Allison Bellman3, Mauli Shah4, Juan C Rodriguez1, Vasanta Putluri5, Abu Hena Mostafa Kamal5, Nagireddy Putluri5,6, Roy F Riascos2,7, Jay-Jiguang Zhu1,7, Yoshua Esquenazi8,9,10, Leomar Y Ballester11,12.   

Abstract

INTRODUCTION: We aimed to evaluate IDH1 p.R132H mutation and 2-hydroxyglutarate (2HG) in cerebrospinal fluid (CSF) as biomarkers for patients with IDH-mutant gliomas.
METHODS: CSF was collected from patients with infiltrating glioma, and 2HG levels were measured by liquid chromatography-mass spectrometry. IDH1 p.R132H mutant allele frequency (MAF) in CSF-ctDNA was measured by digital droplet PCR (ddPCR). Tumor volume was measured from standard-of-care magnetic resonance images.
RESULTS: The study included 48 patients, 6 with IDH-mutant and 42 with IDH-wildtype gliomas, and 57 samples, 9 from the patients with IDH-mutant and 48 from the patients with IDH-wildtype gliomas. ctDNA was detected in 7 of the 9 samples from patients with IDH-mutant glioma, and IDH1 p.R132H mutation was detected in 5 of the 7 samples. The MAF ranged from 0.3 to 39.95%. Total 2HG level, D-2HG level, and D/L-2HG ratio in CSF were significantly higher in patients with IDH-mutant gliomas than in patients with IDH-wildtype gliomas. D-2HG level and D/L-2HG ratio correlated with total tumor volume in patients with IDH-mutant gliomas but not in patients with IDH-wildtype gliomas.
CONCLUSION: Our results suggest that detection of IDH1 p.R132H mutation by ddPCR and increased D-2HG level in CSF may help identify IDH-mutant gliomas. Our results also suggest that D-2HG level and D/L-2HG ratio correlate with tumor volume in patients with IDH-mutant gliomas. Further prospective studies with larger cohorts are needed to validate these findings.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Astrocytoma; Cerebrospinal fluid; Circulating tumor DNA; D-2-hydroxyglutarate (D-2HG); Gliomas; IDH1; Oligodendroglioma

Mesh:

Substances:

Year:  2022        PMID: 35816267     DOI: 10.1007/s11060-022-04060-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  20 in total

1.  Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Authors:  Nicholas J Roberts; Linping Zhang; Filip Janku; Amanda Collins; Ren-Yuan Bai; Verena Staedtke; Saurabh Saha; Shibin Zhou; Anthony W Rusk; David Tung; Maria Miller; Jeffrey Roix; Kristen V Khanna; Ravi Murthy; Robert S Benjamin; Thorunn Helgason; Ariel D Szvalb; Justin E Bird; Sinchita Roy-Chowdhuri; Halle H Zhang; Yuan Qiao; Baktiar Karim; Jennifer McDaniel; Amanda Elpiner; Alexandra Sahora; Joshua Lachowicz; Brenda Phillips; Avenelle Turner; Mary K Klein; Gerald Post; Luis A Diaz; Gregory J Riggins; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Chetan Bettegowda; David L Huso; Mary Varterasian
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

2.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

3.  Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.

Authors:  Juliya Kalinina; Jun Ahn; Narra S Devi; Liya Wang; Yuancheng Li; Jeffrey J Olson; Michael Glantz; Thomas Smith; Ella L Kim; Alf Giese; Randy L Jensen; Clark C Chen; Bob S Carter; Hui Mao; Miao He; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2016-06-23       Impact factor: 12.531

4.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

5.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

Review 6.  Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets.

Authors:  Junfeng Bi; Sudhir Chowdhry; Sihan Wu; Wenjing Zhang; Kenta Masui; Paul S Mischel
Journal:  Nat Rev Cancer       Date:  2019-12-05       Impact factor: 69.800

7.  Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.

Authors:  Elena I Pentsova; Ronak H Shah; Jiabin Tang; Adrienne Boire; Daoqi You; Samuel Briggs; Antonio Omuro; Xuling Lin; Martin Fleisher; Christian Grommes; Katherine S Panageas; Fanli Meng; S Duygu Selcuklu; Shahiba Ogilvie; Natalie Distefano; Larisa Shagabayeva; Marc Rosenblum; Lisa M DeAngelis; Agnes Viale; Ingo K Mellinghoff; Michael F Berger
Journal:  J Clin Oncol       Date:  2016-05-09       Impact factor: 44.544

8.  Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.

Authors:  Alexandra M Miller; Ronak H Shah; Elena I Pentsova; Maryam Pourmaleki; Samuel Briggs; Natalie Distefano; Youyun Zheng; Anna Skakodub; Smrutiben A Mehta; Carl Campos; Wan-Ying Hsieh; S Duygu Selcuklu; Lilan Ling; Fanli Meng; Xiaohong Jing; Aliaksandra Samoila; Tejus A Bale; Dana W Y Tsui; Christian Grommes; Agnes Viale; Mark M Souweidane; Viviane Tabar; Cameron W Brennan; Anne S Reiner; Marc Rosenblum; Katherine S Panageas; Lisa M DeAngelis; Robert J Young; Michael F Berger; Ingo K Mellinghoff
Journal:  Nature       Date:  2019-01-23       Impact factor: 49.962

9.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

Authors:  Leticia De Mattos-Arruda; Regina Mayor; Charlotte K Y Ng; Britta Weigelt; Francisco Martínez-Ricarte; Davis Torrejon; Mafalda Oliveira; Alexandra Arias; Carolina Raventos; Jiabin Tang; Elena Guerini-Rocco; Elena Martínez-Sáez; Sergio Lois; Oscar Marín; Xavier de la Cruz; Salvatore Piscuoglio; Russel Towers; Ana Vivancos; Vicente Peg; Santiago Ramon y Cajal; Joan Carles; Jordi Rodon; María González-Cao; Josep Tabernero; Enriqueta Felip; Joan Sahuquillo; Michael F Berger; Javier Cortes; Jorge S Reis-Filho; Joan Seoane
Journal:  Nat Commun       Date:  2015-11-10       Impact factor: 14.919

Review 10.  Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.

Authors:  Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Trends Cancer       Date:  2018-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.